Drugs / Sacrosidase
Sacrosidase
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | SUCRAID | — | 1998-04-09 | fda.gov ↗ |
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05703009 | Jun 2023 → Jan 2024 | disorder of carbohydrate transmembrane transport and absorption | QOL Medical, LLC | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05480761 | Aug 2022 → Sep 2024 | congenital sucrase-isomaltase deficiency | QOL Medical, LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02784067 | May 2016 → Dec 2017 | congenital sucrase-isomaltase deficiency | QOL Medical, LLC | Withdrawn | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sacrosidase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05703009 ↗ |
| Known as | .beta.-fructofuranosidase | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201487 ↗ |
| Known as | Sacrosidasa | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201487 ↗ |
| Known as | Sucraid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02784067 ↗ |
| Modality | Protein / enzyme biologic | “the enzyme sacrosidase, the active ingredient.” NCT05480761 ↗ |
| Route | Oral | “administered orally” NCT02784067 ↗ |